The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 244.00
Bid: 238.00
Ask: 250.00
Change: 19.00 (8.44%)
Spread: 12.00 (5.042%)
Open: 225.00
High: 244.00
Low: 225.00
Prev. Close: 225.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron Pharmaceuticals Notice of Interim Results

10 Aug 2016 07:00

RNS Number : 7149G
Faron Pharmaceuticals Oy
10 August 2016
 

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Notice of Interim Results

 

TURKU - FINLAND 10 August 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, will announce its Interim Results for the six months ended 30th June, 2016 on Monday 5th September, 2016.

 

Dr Markku Jalkanen, Chief Executive Officer, will host a presentation for analysts at 9am BST on the day of results at Panmure Gordon's offices, One New Change, London EC4M 9AF.

 

- END -

 

For more information, please contact:

 

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807

E-mail: katja.wallenlind@faronpharmaceuticals.com 

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

 

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley / Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

 

Whitman Howard Limited, Joint Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

 

About Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron's scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company's lead candidate Traumakine® is in development for the treatment of Acute Respiratory Distress Syndrome (ARDS), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in a pan-European pivotal Phase III study (INTEREST). Additionally, Faron is developing Clevegen®, a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology (TIET) and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORSSMFLUFMSELA
Date   Source Headline
6th Mar 201812:54 pmRNSHolding(s) in Company
5th Mar 201810:12 amRNSHolding(s) in Company
2nd Mar 20181:30 pmRNSHolding(s) in Company
2nd Mar 20181:25 pmRNSHolding(s) in Company
1st Mar 201812:42 pmRNSHoldings in Company
1st Mar 201812:41 pmRNSHoldings in Company
26th Feb 20181:37 pmRNSIssue of Equity
21st Feb 20183:31 pmRNSResults of Placing & Issue of Equity
21st Feb 20187:00 amRNSFaron hosts R&D Day today in London
16th Feb 20187:00 amRNSProposed Placing to raise up to £15m
5th Feb 20187:00 amRNSSecond Traumakine manufacturing site established
1st Feb 20187:00 amRNSFaron Announces Clevegen Grant of European Patent
29th Jan 20187:00 amRNSFDA grants Fast Track Designation for Traumakine®
24th Jan 20187:00 amRNSFDA approval of Faron's Traumakine® IND
19th Dec 20177:00 amRNSINFORAAA trial receives recommendation from IDMC
14th Dec 20177:00 amRNSFaron announces R&D Day in February 2018
11th Dec 20177:32 amRNSRecruitment completed in Traumakine INTEREST Trial
6th Dec 20176:06 pmRNSHolding(s) in Company
1st Dec 20172:55 pmRNSHoldings in Company
1st Dec 20177:01 amRNSAppointment of Chief Commercial Officer
24th Nov 201710:23 amRNSHolding(s) in Company
21st Nov 20177:00 amRNSGrant of options
20th Nov 20177:00 amRNSChange of Adviser
16th Oct 20179:00 amRNSHolding(s) in Company
13th Oct 20179:00 amRNSDirector/PDMR Shareholding
11th Oct 20172:00 pmRNSIssue of Equity & PDMR Shareholding
9th Oct 20174:30 pmRNSResult of Placing & Subscription & Issue of Equity
5th Oct 20177:00 amRNSProposed Placing and Subscription
2nd Oct 20177:00 amRNSTraumakine Receives PIM Designation from MHRA
11th Sep 20173:19 pmRNSDirectors Dealings
6th Sep 20177:00 amRNSInterim Results
4th Sep 20177:00 amRNSFDA advises Faron to proceed directly to BLA
4th Aug 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
28th Jul 20179:34 amRNSHolding(s) in Company
10th Jul 20174:51 pmRNSHolding(s) in Company
10th Jul 20177:00 amRNSNotice of Results
16th Jun 20172:43 pmRNSDirector/PDMR Shareholding
1st Jun 20177:00 amRNSExercise of Warrants and Options
30th May 20172:06 pmRNSHoldings in Company
22nd May 201711:31 amRNSDirector/PDMR Shareholding
22nd May 20177:00 amRNSDirector/PDMR Shareholding
18th May 20179:20 amRNSDirector/PDMR Shareholding
16th May 201712:00 pmRNSResult of AGM
8th May 20174:40 pmRNSSecond Price Monitoring Extn
8th May 20174:35 pmRNSPrice Monitoring Extension
8th May 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
27th Apr 20175:57 pmRNSExercise of Warrants
26th Apr 201712:32 pmRNSDirector's dealings
21st Apr 20175:56 pmRNSDirector/PDMR Shareholding
19th Apr 20177:00 amRNSNotice of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.